The FDA cleared the investigational new drug application of IDE849, a potential first-in-class DLL3-targeted antibody-drug ...

A delta-like ligand 3 (DLL3) targeting radiopharmaceutical biologic therapy, ABD-147 is engineered to deliver Actinium-225 (225Ac), an alpha-emitting radioisotope, to solid tumours that express ...

Molecular Partners leverages DARPins for oncology treatments, but Novartis' exit raises concerns. Click here to read why ...

Delta-like ligand (DLL3) antibody-drug conjugate (ADC) for the treatment of extensive-stage small cell lung cancer (ES-SCLC), will be presented during a poster session at the 2025 American Society ...

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in ...

Engineered by the company’s researchers, this immunotherapy targets delta-like ligand 3 (DLL3), a protein prevalent in the majority of SCLC cells but rare in healthy cells. The therapy works by ...

Targeting to evaluate IDE849 (SHR-4849) in SCLC, NETs, and other DLL3-upregulated solid tumors, and in combination with IDE161/PARG to potentially enhance durability Targeting to present clinical ...

Dosing underway in Phase 1 clinical trial for ABD-147 (DLL3-targeting radiopharmaceutical) in patients with extensive stage small cell lung cancer and large cell neuroendocrine carcinoma of the ...

Zai Lab to Present Data from Phase 1 Trial of DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310 at 2025 ASCO Annual Meeting - Zai Lab will highlight potential of ZL-1310 as a promising ...

SOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted ...

Delta-like ligand (DLL3) antibody-drug conjugate (ADC) for the treatment of extensive-stage small cell lung cancer (ES-SCLC), will be presented during a poster session at the 2025 American Society of ...